<DOC>
	<DOCNO>NCT00664482</DOCNO>
	<brief_summary>Argos Therapeutics , Inc. , ( Argos ) propose study AGS-006 subject newly diagnose resectable pancreatic cancer . The AGS 006 immunotherapeutic may potentially offer desired additional option conventional treatment pancreatic carcinoma .</brief_summary>
	<brief_title>A Single-Patient Study Using AGS 006</brief_title>
	<detailed_description>Single-patient , open-label clinical study : - Events Pre-Treatment Period : 1 . Resection pancreatic cancer , 2 . RNA acquisition tumor specimen , 3 . RNA amplification , 4 . Infectious disease testing , 5 . Autoimmune disease testing , 6 . Two blood draw immune response monitoring , 7 . Production leukapheresis , 8 . Dendritic cell electroporation RNA immunotherapeutic production ; - Events Induction Period : 1 . Administer investigative treatment every 2 week total five dos , follow dose every 4 week total four dos , 2 . Two Induction Period blood draw ( Week 6 Week 12 ) immune response monitoring , 3 . One leukapheresis ( Week 14 ) immune response monitoring ; - Events Booster Period : 1 . Dose every 3 month progression 2 year first AGS treatment , 2 . Potentially , one leukapheresis immune response monitor 12 month first dose , 3 . One blood draw 2 week follow dose Week 36 ( 1st booster dose ) ( approximately Week 38 ) ; , - Events study Close-Out : 1 . Close-Out upon progression 28 day follow immune response monitor 2 year first dose</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>A male subject 18 year age old newly diagnose resectable pancreatic cancer , opinion investigator , suitable participation study eligible inclusion follow criterion apply : 1 . Able abstain take prohibited prescription prohibit nonprescription drug . 2 . Ability communicate effectively study personnel ; consider reliable , willing , cooperative term compliance Protocol requirement . 3 . Voluntary inform consent give participate study . 1 . Any serious medical condition cardiopulmonary disease , circulatory compromise , hepatic renal dysfunction , illness consider investigator constitute unwarranted high risk investigational treatment . 2 . Active autoimmune disease include , limited : 3 . Active , acute , chronic clinically significant infection include human immunodeficiency virus ( HIV ) viral hepatitis . 4 . Known hypersensitivity dimethyl sulfoxide ( DMSO ) . 5 . Body weight less 30 kg .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>